4MARUENDA J,BHATNAGAR V.Lowenthal DT1 Hypertension in the elderly with coexisting benign p rostatic hyperp lasia1[J].Urology,1999,53 (Suppl 3A):72131.
5MICHEL MC,HEEMANN U,SCHUMACHER H,et al.1Association ofhypertension with symp toms of benign p rostatic hyperplasia1[J].J Urol,2004,172:1390-1393.
6PAREEK G,SHEVCHUK M,ARMENAKAS NA,et al.The effect offinasteride on the exp ression of vascular endothelial growth factor and microvessel density:a possible mechanism for decreased prostaticbleeding in treated patients1[J].J Urol,2003,169:202231.
7KOBAYASHI S,TANG R,SHAPIRO E,et al.Characterization localization of prostatic alphal aderenoceptors using radio ligand binding on slide-mounted tissue section[J].J Urol,1993,150 (6),2002-2006.
8CHEOL KWAK,JEONG KI LEE,AND JA HYEON KU.High-dose terazosin therapy (5 mg) in korean patients with lower urinary tract symptoms with or without concomitant hypertension:A prospective,open-label study[J].J Yonsei Med J,2007,31,48(6):994-1000.
9TURKERI LN,OXYUREK M,ERSEV D,et al.Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia[J].Arch Esprol,2001,54:191-196.
10GLASSMAN DT,CHON JK,BORKOWSKI A,et al.Combined effect of terazpsinand finasteride on apoptisis,cell proliferation and transforming growth factor-B expression in benign prostatic hyperplasia[J].The Prostate,2001,46:45-51.
